Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

2026-02-26 - 21:23

NEW YORK -- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported its full-year 2025 financial results and provided business updates. Read More